^
Association details:
| Biomarker: | EGFR S768I |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
Excerpt:
...a 52-year-old Chinese female with no smoking history...the patient was diagnosed with lung adenocarcinoma....Molecular pathology suggested EGFR exon 20 p.S768I mutation (2303G>T)...the patient started taking afatinib (40 mg/day) with bevacizumab. The chest CT scan revealed the metastases shrank obviously after 1 month (Figure 3C)....The efficacy evaluation was partial response. Now, the patient has PFS for 6 month (Table 1).
